We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · November 29, 2020

Concentrations of Biologic Agents in Patients With IBD During Pregnancy and in Their Infants

Alimentary Pharmacology & Therapeutics


Additional Info

Alimentary Pharmacology & Therapeutics
Infliximab, Adalimumab and Vedolizumab Concentrations Across Pregnancy and Vedolizumab Concentrations in Infants Following Intrauterine Exposure
Aliment. Pharmacol. Ther. 2020 Nov 01;52(10)1551-1562, E Flanagan, PR Gibson, EK Wright, GT Moore, MP Sparrow, W Connell, MA Kamm, J Begun, B Christensen, P De Cruz, E Shelton, D Dowling, JM Andrews, SJ Brown, O Niewiadomski, MG Ward, O Rosella, G Rosella, KV Kiburg, AL Ross, SJ Bell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading